[Hyponatremia in Liver Cirrhosis]

Area of Science:

• Hepatology
• Nephrology
• Endocrinology

Background:

• Hyponatremia (serum sodium < 130 meq/L) is a frequent complication in advanced liver cirrhosis.
• It is often dilutional and associated with hypoalbuminemia and portal hypertension.
• Hyponatremia worsens prognosis, increasing risks of spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, and mortality.

Purpose of the Study:

• To review the pathophysiology of hyponatremia in liver cirrhosis.
• To explore current and emerging therapeutic strategies for managing hyponatremia in cirrhotic patients.

Main Methods:

• Literature review of pathophysiology and treatment modalities for hyponatremia in liver cirrhosis.
• Focus on conventional therapies and novel agents, including vasopressin receptor antagonists.

Main Results:

• Conventional treatments (albumin, fluid restriction, diuretics) are often insufficient.
• Selective vasopressin receptor antagonists represent a promising therapeutic avenue.

Conclusions:

• Hyponatremia is a critical factor influencing morbidity and mortality in liver cirrhosis.
• Effective management, potentially including vasopressin receptor antagonists, is crucial for improving patient outcomes.